ZA200401594B - Piperidine derivatives useful as CCR5 antagonists. - Google Patents

Piperidine derivatives useful as CCR5 antagonists. Download PDF

Info

Publication number: ZA200401594B
Authority: ZA; South Africa
Prior art keywords: alkyl; group; composition; substance; aryl
Prior art date: 2001-08-29

Application number

ZA200401594A

Other languages

English (en)

Inventor

Anandan Palani

Jack D Scott

Michael W Miller

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-29

Filing date

2004-02-25

Publication date

2004-11-24

2004-02-25 Application filed by Schering Corp filed Critical Schering Corp

2004-11-24 Publication of ZA200401594B publication Critical patent/ZA200401594B/en

Links

102100035875 C-C chemokine receptor type 5 Human genes 0.000 title description 6
101710149870 C-C chemokine receptor type 5 Proteins 0.000 title description 6
239000005557 antagonist Substances 0.000 title description 5
150000003053 piperidines Chemical class 0.000 title description 3
125000000217 alkyl group Chemical group 0.000 claims description 78
150000001875 compounds Chemical class 0.000 claims description 42
238000011282 treatment Methods 0.000 claims description 30
125000003118 aryl group Chemical group 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 25
-1 cycloheteroalkyl Chemical group 0.000 claims description 23
229910052739 hydrogen Inorganic materials 0.000 claims description 22
239000000126 substance Substances 0.000 claims description 22
238000000034 method Methods 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 20
125000000753 cycloalkyl group Chemical group 0.000 claims description 19
125000001188 haloalkyl group Chemical group 0.000 claims description 19
241000725303 Human immunodeficiency virus Species 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
125000001072 heteroaryl group Chemical group 0.000 claims description 16
125000004432 carbon atom Chemical group C* 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
206010052779 Transplant rejections Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
210000000056 organ Anatomy 0.000 claims description 10
206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
201000006417 multiple sclerosis Diseases 0.000 claims description 9
125000001424 substituent group Chemical group 0.000 claims description 9
230000000840 anti-viral effect Effects 0.000 claims description 8
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
239000012453 solvate Substances 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
206010012438 Dermatitis atopic Diseases 0.000 claims description 6
206010020751 Hypersensitivity Diseases 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
230000007815 allergy Effects 0.000 claims description 6
206010003246 arthritis Diseases 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 6
201000008937 atopic dermatitis Diseases 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 4
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 4
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 4
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
150000002431 hydrogen Chemical class 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
125000003373 pyrazinyl group Chemical group 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
125000003003 spiro group Chemical group 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 8
239000003443 antiviral agent Substances 0.000 claims 4
NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 claims 4
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 4
YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 claims 2
NIDRYBLTWYFCFV-SEDUGSJDSA-N (+)-calanolide b Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-SEDUGSJDSA-N 0.000 claims 2
HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 claims 2
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims 2
ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 claims 2
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 2
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 2
108010032976 Enfuvirtide Proteins 0.000 claims 2
108010065805 Interleukin-12 Proteins 0.000 claims 2
108010002350 Interleukin-2 Proteins 0.000 claims 2
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 2
RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 2
229960004748 abacavir Drugs 0.000 claims 2
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
229960003205 adefovir dipivoxil Drugs 0.000 claims 2
229960001830 amprenavir Drugs 0.000 claims 2
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 2
RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 claims 2
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 2
229960002656 didanosine Drugs 0.000 claims 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
229960003804 efavirenz Drugs 0.000 claims 2
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 2
MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims 2
PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims 2
229960002062 enfuvirtide Drugs 0.000 claims 2
125000001475 halogen functional group Chemical group 0.000 claims 2
229960001936 indinavir Drugs 0.000 claims 2
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 2
229960001627 lamivudine Drugs 0.000 claims 2
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
229950004697 lasinavir Drugs 0.000 claims 2
229950005339 lobucavir Drugs 0.000 claims 2
KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 claims 2
229950003557 lodenosine Drugs 0.000 claims 2
229960000884 nelfinavir Drugs 0.000 claims 2
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 2
229960000689 nevirapine Drugs 0.000 claims 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
229960000329 ribavirin Drugs 0.000 claims 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
229960000311 ritonavir Drugs 0.000 claims 2
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
229960001852 saquinavir Drugs 0.000 claims 2
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
229960001203 stavudine Drugs 0.000 claims 2
BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims 2
229960000523 zalcitabine Drugs 0.000 claims 2
229960002555 zidovudine Drugs 0.000 claims 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 2
101000948583 Bacillus subtilis (strain 168) GTP pyrophosphokinase YjbM Proteins 0.000 claims 1
101100083253 Caenorhabditis elegans pho-1 gene Proteins 0.000 claims 1
235000010290 biphenyl Nutrition 0.000 claims 1
239000004305 biphenyl Substances 0.000 claims 1
125000006267 biphenyl group Chemical group 0.000 claims 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
235000021410 healthy eating index Nutrition 0.000 claims 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 claims 1
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
125000004122 cyclic group Chemical group 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
125000006413 ring segment Chemical group 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000011575 calcium Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229910014585 C2-Ce Inorganic materials 0.000 description 2
102000009410 Chemokine receptor Human genes 0.000 description 2
108050000299 Chemokine receptor Proteins 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
150000001204 N-oxides Chemical class 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
125000002877 alkyl aryl group Chemical group 0.000 description 2
239000002585 base Substances 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241001482630 Epinnula magistralis Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
229910014332 N(SO2CF3)2 Inorganic materials 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
241000862969 Stella Species 0.000 description 1
241000534944 Thia Species 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000011225 antiretroviral therapy Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
125000005135 aryl sulfinyl group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
150000004648 butanoic acid derivatives Chemical class 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000005182 global health Effects 0.000 description 1
150000002315 glycerophosphates Chemical class 0.000 description 1
239000011440 grout Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
125000005368 heteroarylthio group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002547 new drug Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000010076 replication Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
208000010648 susceptibility to HIV infection Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
150000003567 thiocyanates Chemical class 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Virology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200401594A 2001-08-29 2004-02-25 Piperidine derivatives useful as CCR5 antagonists. ZA200401594B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31568301P	2001-08-29	2001-08-29

Publications (1)

Publication Number	Publication Date
ZA200401594B true ZA200401594B (en)	2004-11-24

Family

ID=23225580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401594A ZA200401594B (en)	2001-08-29	2004-02-25	Piperidine derivatives useful as CCR5 antagonists.

Country Status (23)

Country	Link
US (4)	US20040010008A1 (pl)
EP (1)	EP1421075B1 (pl)
JP (2)	JP4223950B2 (pl)
KR (1)	KR20040029057A (pl)
CN (1)	CN1304389C (pl)
AR (1)	AR036366A1 (pl)
AT (1)	ATE328879T1 (pl)
BR (1)	BR0212108A (pl)
CA (1)	CA2457861A1 (pl)
CY (1)	CY1105198T1 (pl)
DE (1)	DE60212146T2 (pl)
DK (1)	DK1421075T3 (pl)
EC (1)	ECSP044993A (pl)
ES (1)	ES2264491T3 (pl)
HU (1)	HUP0402019A3 (pl)
IL (1)	IL160060A0 (pl)
MX (1)	MXPA04001886A (pl)
NO (1)	NO20041266L (pl)
PL (1)	PL368827A1 (pl)
PT (1)	PT1421075E (pl)
RU (1)	RU2004109510A (pl)
WO (1)	WO2003020716A1 (pl)
ZA (1)	ZA200401594B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0108876D0 (en) *	2001-04-09	2001-05-30	Novartis Ag	Organic Compounds
KR20040013090A (ko)	2001-07-02	2004-02-11	아스트라제네카 아베	케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
SE0200843D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
GB0223223D0 (en)	2002-10-07	2002-11-13	Novartis Ag	Organic compounds
WO2004035541A1 (en) *	2002-10-15	2004-04-29	Janssen Pharmaceutica, N.V.	Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
SE0300957D0 (sv)	2003-04-01	2003-04-01	Astrazeneca Ab	Chemical compounds
CN1898231B (zh)	2003-11-03	2010-10-27	先灵公司	用作趋化因子受体抑制剂的双六氢吡啶衍生物
JP2007513082A (ja) *	2003-11-10	2007-05-24	シエーリングアクチエンゲゼルシャフト	Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
BRPI0509803A (pt)	2004-04-13	2007-09-18	Incyte Corp	derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
US7880002B2 (en)	2004-12-29	2011-02-01	Millennium Pharmaceuticals, Inc.	Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en)	2004-12-29	2009-12-22	Millennium Pharmaceuticals, Inc.	Compounds useful as chemokine receptor antagonists
EP1844037A1 (en) *	2005-01-20	2007-10-17	Pfizer Limited	Chemical compounds
EP1858886A1 (en) *	2005-02-23	2007-11-28	Schering Corporation	Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
US20070010565A1 (en) *	2005-04-25	2007-01-11	Olaf Prien	New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
WO2007011293A1 (en)	2005-07-21	2007-01-25	Astrazeneca Ab	Novel piperidine derivatives
US8119661B2 (en) *	2007-09-11	2012-02-21	Astrazeneca Ab	Piperidine derivatives and their use as muscarinic receptor modulators
CN101801952A (zh)	2007-10-01	2010-08-11	弗·哈夫曼-拉罗切有限公司	用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物
EP2297137A1 (en) *	2008-06-18	2011-03-23	F. Hoffmann-La Roche AG	Novel heteroaryl carboxamide derivatives
GB201017345D0 (en)	2010-10-14	2010-11-24	Proximagen Ltd	Receptor antagonists
AP2016009276A0 (en)	2013-12-19	2016-06-30	Bayer Pharma AG	Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
SG11201604949XA (en)	2013-12-19	2016-07-28	Bayer Pharma AG	Substituted piperidinyl-tetrahydroquinolines
CN106029648A (zh)	2013-12-19	2016-10-12	拜耳制药股份公司	作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
WO2015091420A1 (de) *	2013-12-19	2015-06-25	Bayer Pharma Aktiengesellschaft	Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
US11311552B2 (en)	2015-04-02	2022-04-26	Proximagen, Llc	Therapies for cancer
US11629196B2 (en)	2020-04-27	2023-04-18	Incelldx, Inc.	Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US12018016B2 (en) *	2021-08-18	2024-06-25	Amgen Inc.	Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4588722A (en) *	1984-01-09	1986-05-13	Janssen Pharmaceutica N.V.	N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) *	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) *	1996-07-10	1999-09-14	Schering Corporation	Muscarinic antagonists for treating memory loss
EP0912515B1 (en) *	1996-07-10	2002-11-13	Schering Corporation	1,4-di-substituted piperidines as muscarinic antagonists
HK1039330B (en) *	1999-05-04	2005-12-09	Schering Corporation	Piperidine derivatives useful as ccr5 antagonists
WO2001030348A1 (en) *	1999-10-25	2001-05-03	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) *	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) *	2001-04-09	2001-05-30	Novartis Ag	Organic Compounds

2002
- 2002-08-27 AR ARP020103217A patent/AR036366A1/es unknown
- 2002-08-28 EP EP02766142A patent/EP1421075B1/en not_active Expired - Lifetime
- 2002-08-28 MX MXPA04001886A patent/MXPA04001886A/es active IP Right Grant
- 2002-08-28 DK DK02766142T patent/DK1421075T3/da active
- 2002-08-28 RU RU2004109510/04A patent/RU2004109510A/ru not_active Application Discontinuation
- 2002-08-28 US US10/229,466 patent/US20040010008A1/en not_active Abandoned
- 2002-08-28 CN CNB028166795A patent/CN1304389C/zh not_active Expired - Fee Related
- 2002-08-28 HU HU0402019A patent/HUP0402019A3/hu unknown
- 2002-08-28 PT PT02766142T patent/PT1421075E/pt unknown
- 2002-08-28 CA CA002457861A patent/CA2457861A1/en not_active Abandoned
- 2002-08-28 DE DE60212146T patent/DE60212146T2/de not_active Expired - Lifetime
- 2002-08-28 KR KR10-2004-7002835A patent/KR20040029057A/ko not_active Withdrawn
- 2002-08-28 WO PCT/US2002/027389 patent/WO2003020716A1/en not_active Ceased
- 2002-08-28 BR BR0212108-5A patent/BR0212108A/pt not_active IP Right Cessation
- 2002-08-28 ES ES02766142T patent/ES2264491T3/es not_active Expired - Lifetime
- 2002-08-28 IL IL16006002A patent/IL160060A0/xx unknown
- 2002-08-28 PL PL02368827A patent/PL368827A1/pl not_active Application Discontinuation
- 2002-08-28 AT AT02766142T patent/ATE328879T1/de not_active IP Right Cessation
- 2002-08-28 JP JP2003524986A patent/JP4223950B2/ja not_active Expired - Fee Related
2003
- 2003-07-29 US US10/628,933 patent/US7384948B2/en not_active Expired - Fee Related
- 2003-07-29 US US10/629,466 patent/US7442703B2/en not_active Expired - Fee Related
2004
- 2004-02-25 ZA ZA200401594A patent/ZA200401594B/en unknown
- 2004-02-27 EC EC2004004993A patent/ECSP044993A/es unknown
- 2004-03-26 NO NO20041266A patent/NO20041266L/no not_active Application Discontinuation
2006
- 2006-09-06 CY CY20061101271T patent/CY1105198T1/el unknown
2008
- 2008-04-17 US US12/104,914 patent/US8034933B2/en not_active Expired - Fee Related
- 2008-05-22 JP JP2008134844A patent/JP2008222722A/ja active Pending

Also Published As

Publication number	Publication date
US8034933B2 (en)	2011-10-11
HUP0402019A3 (en)	2009-07-28
DE60212146T2 (de)	2007-06-06
EP1421075A1 (en)	2004-05-26
JP4223950B2 (ja)	2009-02-12
EP1421075B1 (en)	2006-06-07
CN1551877A (zh)	2004-12-01
CY1105198T1 (el)	2010-03-03
IL160060A0 (en)	2004-06-20
CA2457861A1 (en)	2003-03-13
PL368827A1 (pl)	2005-04-04
JP2005502682A (ja)	2005-01-27
DE60212146D1 (de)	2006-07-20
US7384948B2 (en)	2008-06-10
US20040092551A1 (en)	2004-05-13
MXPA04001886A (es)	2004-06-15
PT1421075E (pt)	2006-10-31
CN1304389C (zh)	2007-03-14
ATE328879T1 (de)	2006-06-15
JP2008222722A (ja)	2008-09-25
US7442703B2 (en)	2008-10-28
US20080214575A1 (en)	2008-09-04
DK1421075T3 (da)	2006-09-18
ES2264491T3 (es)	2007-01-01
WO2003020716A1 (en)	2003-03-13
BR0212108A (pt)	2004-08-24
KR20040029057A (ko)	2004-04-03
US20040092745A1 (en)	2004-05-13
US20040010008A1 (en)	2004-01-15
HK1061563A1 (en)	2004-09-24
HUP0402019A2 (hu)	2005-02-28
AR036366A1 (es)	2004-09-01
RU2004109510A (ru)	2005-10-20
ECSP044993A (es)	2004-04-28
NO20041266L (no)	2004-03-26

Publication	Publication Date	Title
ZA200401594B (en)	2004-11-24	Piperidine derivatives useful as CCR5 antagonists.
CN109715624B (zh)	2022-08-16	用于治疗hbv感染的新颖治疗剂
CA2764177C (en)	2018-06-05	Inhibitors of influenza viruses replication
RU2737190C2 (ru)	2020-11-25	Ингибиторы репликации вируса гриппа, способы их применения и использование
EP3601216B1 (en)	2023-10-25	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
KR101987994B1 (ko)	2019-06-11	치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법
AU751453B2 (en)	2002-08-15	Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
SA99200059A (ar)	2005-12-03	مركبات إميدازول جديدة مستبدلة
WO2013189237A1 (zh)	2013-12-27	穿心莲内酯类似物及其治疗的应用
WO2014066491A1 (en)	2014-05-01	N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
HU224010B1 (hu)	2005-04-28	Zidovudin, 1592U89 és 3TC vagy szinergetikus kombinációi
TW201738241A (zh)	2017-11-01	流感病毒複製之抑制劑
AU2020286339A1 (en)	2021-01-21	Compositions and methods for inhibiting kinases
CN112062800B (zh)	2022-11-18	核苷化合物的氨基磷酸酯衍生物及其用途
EP3793550A2 (en)	2021-03-24	Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
CN112010916B (zh)	2022-12-27	核苷化合物的氨基磷酸酯衍生物及其用途
US20230391807A1 (en)	2023-12-07	Antiviral prodrug compounds
CN110272425B (zh)	2022-11-04	吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
WO2023207942A1 (zh)	2023-11-02	用于治疗或预防冠状病毒感染的核苷类药物及其用途
TWI746532B (zh)	2021-11-21	作為人類鼻病毒抑制劑之炔基核苷類似物
WO2017088731A1 (zh)	2017-06-01	八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN115768778A (zh)	2023-03-07	苄氧基磷酸(膦酸)酯化合物
CN116217621B (zh)	2023-08-11	一种核苷类双前药、合成方法及应用
TW202132285A (zh)	2021-09-01	經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
JP4887305B2 (ja)	2012-02-29	Ｈｉｖの治療に有用な化合物